Roche Holding | ROG - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 6.88B 156M 2026-09
Alcon AG USD 44M 253M 2026-06
Almirall EUR 71.55M 41.32M 2026-06
Amgen USD 4.61B 777M 2026-06
AstraZeneca USD 4.66B 1.5B 2026-09
Bayer EUR 827M 2.7B 2026-06
Biogen USD 419.5M 663.3M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Eli Lilly USD 12.46B 2.68B 2026-06
Fresenius EUR 719M 118M 2026-06
Fresenius Medical Care EUR 537.27M 269.27M 2026-06
Genmab DKK 407M 182M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.86B 251M 2026-09
GRIFOLS EUR 394M 65M 2026-09
Hikma Pharmaceutical USD 348M 161M 2025-12
Lakefront Biotherapeutics EUR -43.51M 20.19M 2026-06
Lonza CHF 673M 243M 2025-06
Merck EUR 1.1B 51M 2026-06
Merck USD 7.33B 6.49B 2026-09
Novartis USD 5.14B 392M 2026-09
Orion EUR 209.9M 33.3M 2026-09
Pfizer USD 667M 4.32B 2026-06
Philips EUR 610M 308M 2026-06
Recordati EUR 203.76M 27.35M 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 4.72B 2.34B 2026-09
UCB EUR 1.29B 571M 2025-12